IP Library Granted Patent US 8,344,125
Granted Patent B2
US 8,344,125 · App. 12/619,382 · Granted Jan 1, 2013

Modified iRNA agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,344,125
App. No.
12/619,382
Granted
Jan 1, 2013
Kind
B2
Abstract

The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a carbohydrate; or a steroid, e.g., cholesterol, which is optionally substituted with at least one carbohydrate. is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.

Claims (44)

1. An iRNA agent comprising a first strand and a second strand, wherein at least one subunit having a formula (I) is incorporated into at least one of said strands:

wherein:

X is N(CO)R 7 , or NR 7 ;

Each of R 3 and R 9 is, independently, H, OR a , or OR b , provided that only one of R 3 or R 9 is OH, OR a , or OR b ;

R 5 is H, or C 1 -C 6 alkyl;

R 7 is C 1 -C 20 alkyl substituted with NR c R d or NHC(O)R d ;

R a is H or:

R b is H or:

Each of A and C is, independently, O or S;

B is OH, O − , or

R c is H or C 1 -C 6 alkyl; and

R d is a carbohydrate radical.

2. The compound of claim 1 , wherein R 3 is OR a .

3. The compound of claim 2 , wherein

and R 3 are trans.

4. The compound of claim 2 , wherein A is O.

5. The compound of claim 2 , wherein A is S.

6. The compound of claim 1 , wherein R 3 is OR b .

7. The compound of claim 2 , wherein R 7 is (CH 2 ) 5 NHR d or (CH 2 ) 5 NHC(O)R d .

8. The compound of claim 2 , wherein R d is chosen from the group of a galactose radical, an N-acetylgalactose radical, or a mannose radical.

9. The compound of claim 1 , wherein R 9 is OR a .

10. The iRNA agent of claim 9 , wherein

and R 9 are trans.

11. The iRNA agent of claim 1 , wherein R 9 is OR b .

12. An iRNA agent comprising a first strand and a second strand, wherein at least one subunit having a formula (I′) is incorporated into at least one of said strands:

wherein:

X is N(CO)R 7 or NR 7 ;

R 9 is OR a , OR b or OH;

R 7 is R d ; or C 1 -C 20 alkyl substituted with NR c R d or NHC(O)R d ;

R a is H or

R b is H or

each of A and C is, independently, O or S; and

B is OH, O − , or

R c is H or C 1 -C 6 alkyl;

R d is a carbohydrate radical.

13. The iRNA agent of claim 12 , wherein R 9 is OR a .

14. The iRNA agent of claim 12 , wherein R 9 is OR b .

15. The iRNA agent of claim 12 , wherein

and R 9 are trans.

16. The iRNA agent of claim 1 , wherein X is N(CO)R 7 .

17. The iRNA agent of claim 16 , wherein R 7 is a C 3 -C 8 alkyl substituted with NHC(O)R d .

18. The iRNA agent of claim 17 , wherein R d is chosen from the group of a galactose radical, an N-acetylgalactose radical, or a mannose radical.

19. The iRNA agent of claim 1 , wherein A is O in each occurrence.

20. The iRNA agent of claim 1 , wherein A is S in at least one occurrence.

Assignments (1)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →